468 related articles for article (PubMed ID: 12182772)
21. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
Prados MD; Seiferheld W; Sandler HM; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1147-52. PubMed ID: 15001257
[TBL] [Abstract][Full Text] [Related]
22. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis.
Gabayan AJ; Green SB; Sanan A; Jenrette J; Schultz C; Papagikos M; Tatter SP; Patel A; Amin P; Lustig R; Bastin KT; Watson G; Burri S; Stea B
Neurosurgery; 2006 Apr; 58(4):701-9; discussion 701-9. PubMed ID: 16575334
[TBL] [Abstract][Full Text] [Related]
23. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients.
Zeng ZC; Tang ZY; Fan J; Zhou J; Qin LX; Ye SL; Sun HC; Wang BL; Li D; Wang JH; Zeng MS; Guo W; Tan YS
Cancer J; 2006; 12(2):113-22. PubMed ID: 16630402
[TBL] [Abstract][Full Text] [Related]
24. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB
J Clin Oncol; 2003 Jun; 21(12):2299-304. PubMed ID: 12805330
[TBL] [Abstract][Full Text] [Related]
26. Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency.
Vasanthan A; Mitsumori M; Park JH; Zhi-Fan Z; Yu-Bin Z; Oliynychenko P; Tatsuzaki H; Tanaka Y; Hiraoka M
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):145-53. PubMed ID: 15629605
[TBL] [Abstract][Full Text] [Related]
27. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
Walker MD; Green SB; Byar DP; Alexander E; Batzdorf U; Brooks WH; Hunt WE; MacCarty CS; Mahaley MS; Mealey J; Owens G; Ransohoff J; Robertson JT; Shapiro WR; Smith KR; Wilson CB; Strike TA
N Engl J Med; 1980 Dec; 303(23):1323-9. PubMed ID: 7001230
[TBL] [Abstract][Full Text] [Related]
28. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
29. EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm.
Baumert BG; Brada M; Bernier J; Kortmann RD; Dehing-Oberije C; Collette L; Davis JB
Radiother Oncol; 2008 Aug; 88(2):163-72. PubMed ID: 18455252
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
31. Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer.
Sur R; Donde B; Falkson C; Ahmed SN; Levin V; Nag S; Wong R; Jones G
Brachytherapy; 2004; 3(4):191-5. PubMed ID: 15607150
[TBL] [Abstract][Full Text] [Related]
32. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019.
Lee WR; Bae K; Lawton C; Gillin M; Morton G; Firat S; Baikadi M; Kuettel M; Greven K; Sandler H
Cancer; 2007 Apr; 109(8):1506-12. PubMed ID: 17340591
[TBL] [Abstract][Full Text] [Related]
33. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
34. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control.
Ewend MG; Brem S; Gilbert M; Goodkin R; Penar PL; Varia M; Cush S; Carey LA
Clin Cancer Res; 2007 Jun; 13(12):3637-41. PubMed ID: 17575228
[TBL] [Abstract][Full Text] [Related]
35. Definitive radiotherapy with interstitial implant boost for squamous cell carcinoma of the tongue base.
Karakoyun-Celik O; Norris CM; Tishler R; Mahadevan A; Clark JR; Goldberg S; Devlin P; Busse PM
Head Neck; 2005 May; 27(5):353-61. PubMed ID: 15726587
[TBL] [Abstract][Full Text] [Related]
36. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
[TBL] [Abstract][Full Text] [Related]
37. Impact of surgery, chemotherapy and irradiation on long term outcome of intracranial malignant non-germinomatous germ cell tumors: results of the German Cooperative Trial MAKEI 89.
Calaminus G; Bamberg M; Jürgens H; Kortmann RD; Sörensen N; Wiestler OD; Göbel U
Klin Padiatr; 2004; 216(3):141-9. PubMed ID: 15175958
[TBL] [Abstract][Full Text] [Related]
38. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
[TBL] [Abstract][Full Text] [Related]
39. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
[TBL] [Abstract][Full Text] [Related]
40. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
